PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: MARKET SEGMENTATION BY PRODUCT • Market segmentation by product • Comparison by product • Progestogens - Market size and forecast 2018-2023 • Corticosteroids - Market size and forecast 2018-2023 • Combination therapies - Market size and forecast 2018-2023 • Other therapeutics - Market size and forecast 2018-2023 • Market opportunity by product PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 11: MARKET TRENDS • Growing awareness about supportive care for cancer patients • Increasing healthcare expenditure • Rising preference for novel therapies PART 12: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 13: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • AbbVie Inc. • ANI Pharmaceuticals Inc. • Bristol-Myers Squibb Co. • Fresenius SE & Co. KGaA • Hikma Pharmaceuticals Plc • Merck & Co. Inc. • Mylan NV • Pfizer Inc. • Sun Pharmaceutical Industries Ltd. • Teva Pharmaceutical Industries Ltd. PART 14: APPENDIX • Research methodology • List of abbreviations • Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Product overview Exhibit 02: Global pharmaceuticals market Exhibit 03: Segments of global pharmaceuticals market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Product - Market share 2018-2023 (%) Exhibit 19: Comparison by product Exhibit 20: Progestogens - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Progestogens - Year-over-year growth 2019-2023 (%) Exhibit 22: Corticosteroids - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Corticosteroids - Year-over-year growth 2019-2023 (%) Exhibit 24: Combination therapies - Market size and forecast 2018-2023 ($ millions) Exhibit 25: Combination therapies - Year-over-year growth 2019-2023 (%) Exhibit 26: Other therapeutics - Market size and forecast 2018-2023 ($ millions) Exhibit 27: Other therapeutics - Year-over-year growth 2019-2023 (%) Exhibit 28: Market opportunity by product Exhibit 29: Customer landscape Exhibit 30: Market share by geography 2018-2023 (%) Exhibit 31: Geographic comparison Exhibit 32: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 33: North America - Year-over-year growth 2019-2023 (%) Exhibit 34: Top 3 countries in North America Exhibit 35: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 36: Europe - Year-over-year growth 2019-2023 (%) Exhibit 37: Top 3 countries in Europe Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 39: Asia - Year-over-year growth 2019-2023 (%) Exhibit 40: Top 3 countries in Asia Exhibit 41: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 42: ROW - Year-over-year growth 2019-2023 (%) Exhibit 43: Top 3 countries in ROW Exhibit 44: Key leading countries Exhibit 45: Market opportunity Exhibit 46: Impact of drivers and challenges Exhibit 47: Vendor landscape Exhibit 48: Landscape disruption Exhibit 49: Vendors covered Exhibit 50: Vendor classification Exhibit 51: Market positioning of vendors Exhibit 52: AbbVie Inc. - Vendor overview Exhibit 53: AbbVie Inc. - Business segments Exhibit 54: AbbVie Inc. - Organizational developments Exhibit 55: AbbVie Inc. - Geographic focus Exhibit 56: AbbVie Inc. - Key offerings Exhibit 57: AbbVie Inc. - Key customers Exhibit 58: ANI Pharmaceuticals Inc. - Vendor overview Exhibit 59: ANI Pharmaceuticals Inc. - Business segments Exhibit 60: ANI Pharmaceuticals Inc. - Organizational developments Exhibit 61: ANI Pharmaceuticals Inc. - Geographic focus Exhibit 62: ANI Pharmaceuticals Inc. - Key offerings Exhibit 63: ANI Pharmaceuticals Inc. - Key customers Exhibit 64: Bristol-Myers Squibb Co. - Vendor overview Exhibit 65: Bristol-Myers Squibb Co. - Business segments Exhibit 66: Bristol-Myers Squibb Co. - Organizational developments Exhibit 67: Bristol-Myers Squibb Co. - Geographic focus Exhibit 68: Bristol-Myers Squibb Co. - Key offerings Exhibit 69: Bristol-Myers Squibb Co. - Key customers Exhibit 70: Fresenius SE & Co. KGaA - Vendor overview Exhibit 71: Fresenius SE & Co. KGaA - Business segments Exhibit 72: Fresenius SE & Co. KGaA - Organizational developments Exhibit 73: Fresenius SE & Co. KGaA - Geographic focus Exhibit 74: Fresenius SE & Co. KGaA - Segment focus Exhibit 75: Fresenius SE & Co. KGaA - Key offerings Exhibit 76: Fresenius SE & Co. KGaA - Key customers Exhibit 77: Hikma Pharmaceuticals Plc - Vendor overview Exhibit 78: Hikma Pharmaceuticals Plc - Business segments Exhibit 79: Hikma Pharmaceuticals Plc - Organizational developments Exhibit 80: Hikma Pharmaceuticals Plc - Geographic focus Exhibit 81: Hikma Pharmaceuticals Plc - Segment focus Exhibit 82: Hikma Pharmaceuticals Plc - Key offerings Exhibit 83: Hikma Pharmaceuticals Plc - Key customers Exhibit 84: Merck & Co. Inc. - Vendor overview Exhibit 85: Merck & Co. Inc. - Business segments Exhibit 86: Merck & Co. Inc. - Organizational developments Exhibit 87: Merck & Co. Inc. - Geographic focus Exhibit 88: Merck & Co. Inc. - Segment focus Exhibit 89: Merck & Co. Inc. - Key offerings Exhibit 90: Merck & Co. Inc. - Key customers Exhibit 91: Mylan NV - Vendor overview Exhibit 92: Mylan NV - Product segments Exhibit 93: Mylan NV - Organizational developments Exhibit 94: Mylan NV - Geographic focus Exhibit 95: Mylan NV - Segment focus Exhibit 96: Mylan NV - Key offerings Exhibit 97: Mylan NV - Key customers Exhibit 98: Pfizer Inc. - Vendor overview Exhibit 99: Pfizer Inc. - Business segments Exhibit 100: Pfizer Inc. - Organizational developments Exhibit 101: Pfizer Inc. - Geographic focus Exhibit 102: Pfizer Inc. - Segment focus Exhibit 103: Pfizer Inc. - Key offerings Exhibit 104: Pfizer Inc. - Key customers Exhibit 105: Sun Pharmaceutical Industries Ltd. - Vendor overview Exhibit 106: Sun Pharmaceutical Industries Ltd. - Business segments Exhibit 107: Sun Pharmaceutical Industries Ltd. - Organizational developments Exhibit 108: Sun Pharmaceutical Industries Ltd. - Geographic focus Exhibit 109: Sun Pharmaceutical Industries Ltd. - Key offerings Exhibit 110: Sun Pharmaceutical Industries Ltd. - Key customers Exhibit 111: Teva Pharmaceutical Industries Ltd. - Vendor overview Exhibit 112: Teva Pharmaceutical Industries Ltd. - Business segments Exhibit 113: Teva Pharmaceutical Industries Ltd. - Organizational developments Exhibit 114: Teva Pharmaceutical Industries Ltd. - Segment focus Exhibit 115: Teva Pharmaceutical Industries Ltd. - Key offerings Exhibit 116: Teva Pharmaceutical Industries Ltd. - Key customers Exhibit 117: Validation techniques employed for market sizing Exhibit 118: Definition of market positioning of vendors

AbbVie Inc., ANI Pharmaceuticals Inc., Bristol-Myers Squibb Co., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals Plc., Merck & Co. Inc., Mylan NV, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.